Boston Scientific Denied New Trial for Stent Patent Infringement
Boston Scientific will not receive a new trial for its patent-infringement case, according to a ruling issued last week by a U.S. district court judge in Texas.
Paul Donovan, spokesman for the company, declined to comment on whether the company will appeal the ruling and said removing the stent from the market had not been contemplated.
A jury decided in February the company’s Taxus Express and Taxus Liberte drug-eluting stents infringe on physician Bruce Saffran’s patent.
The company must pay Saffron $431 million plus interest on royalties.